A Phase 1, Open-Label Study to Assess the Single Dose Pharmacokinetics of Suspension and Capsule Formulations of SR419 and Repeat Dose Pharmacokinetics of Capsule Formulation of SR419, and to Assess the Effect of a High-Fat Meal on the Pharmacokinetics of SR419 in Healthy Subjects
Latest Information Update: 09 Aug 2021
At a glance
- Drugs SR 419 (Primary)
- Indications Neuropathic pain
- Focus Pharmacokinetics
- Sponsors SIMR Biotech
- 24 Mar 2021 Status changed from recruiting to completed.
- 28 Feb 2021 Status changed from not yet recruiting to recruiting.
- 13 Jan 2021 New trial record